EGFR and head and neck squamous cell carcinoma: Besides, Cetuximab, a monoclonal targeting the extracellular domain of EGFR, is currently the sole targeted therapy that is approved in combination with a doublet of platinum and 5FU in first-line R/M SCCHN (5).